Join our daily newsletter At The Bell to receive exclusive market insights
- Creso Pharma (CPH) strengthens its board with the appointment of William Lay as CEO and Managing Director
- Additionally, Bruce Linton has been appointed as Non-Executive Director and Micheline McKay has been appointed as Executive Director
- Mr Lay is an experienced cannabis executive and was previously Executive Vice President – Strategy, Orientation & Operations at Creso Pharma
- In his new roles as CEO and Managing Director, Mr Lay will progress Creso Pharma’s North American focused growth strategy as well as its proposed NASDAQ dual listing
- Creso Pharma was down 4.44 per cent on the market with shares trading at 8.6 cents at the conclusion of the trading day
Creso Pharma (CPH) has strengthened its board with the appointment of William Lay as CEO and Managing Director.
Additionally, Bruce Linton has been appointed as Non-Executive Director and Micheline McKay has been appointed as Executive Director.
Mr Lay is an experienced cannabis executive and was previously Executive Vice President – Strategy, Origination & Operations at Creso Pharma.
Prior to joining Creso Pharma, he worked at BMO Capital Markets and Canopy Growth Corporation where he was Associate Director.
In his new roles as CEO and Managing Director, Mr Lay will progress Creso Pharma’s North American focused growth strategy as well as its proposed NASDAQ dual listing.
He will also oversee the company’s global operations including its Swiss division and potential new markets.
“I am excited about the future growth potential of Creso Pharma. Several of our business units are at inflection points and have the opportunity to grow substantially in the future,” Mr Lay said.
Mr Linton has been appointed as a Non-Executive Director in addition to his continuing role as a strategic consultant.
He is a leading cannabis executive and has had experience as a founder, CEO, board member and advisor to a number of cannabis companies.
Before joining Creso Pharma Mr Linton was founder, Chairman and CEO of Canopy, Executive Chairman of Gage Cannabis and a Director at Mind Medicines.
As a Non-Executive Director of Creso Pharma, he will provide strategic advice on the company’s operations and will become involved in progressing corporate and operational initiatives with a focus on North America.
“I have known and thought highly of Creso’s products for several years now. I began formally advising the company less than a year ago, seeking to assist in global adoption of these products,” Mr Linton stated.
“This next step is intended to accelerate mergers and acquisitions that allow for this objective to take place.”
Mrs MacKay has 22 years of experience in the regulatory environment including pharmaceuticals, government-related industries and medical devices.
Currently, she is the Corporate Manager of Creso Pharma’s Canadian subsidiary, Mernova Medical and is responsible for human resources, quality assurance and regulatory affairs.
As an Executive Director, she will further strengthen the company’s board through her experience in government and pharmaceutical industry regulation.
Creso Pharma was down 4.44 per cent on the market with shares trading at 8.6 cents at the conclusion of the trading day.
